Amol Akhade: Seeking insights on DYPD mutation testing in cancer treatment
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“Just want to ask my oncologist colleagues and friends from India and all over the world –
Do you routinely do DYPD mutation testing for each and every cancer patient who gets 5 FU or capecitabine in your institution?
Or only for those with comorbidities?
Or only after toxicity?
Do participate in this survey on X (Twitter).”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023